Tisagenlecleucel for Follicular Lymphoma
(ELARA Trial)

Recruiting in Palo Alto (17 mi)

+45 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Novartis Pharmaceuticals

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

Eligibility Criteria

This trial is for adults with Follicular Lymphoma grades 1, 2, or 3A that hasn't responded to treatment or has come back. Participants must have measurable disease. Those with transformed lymphoma, brain involvement by cancer, previous stem cell transplant, grade 3B lymphoma, or prior gene or anti-CD19 therapy can't join.

Inclusion Criteria

Radiographically measurable disease at screening

My Follicular Lymphoma has returned or is not responding to treatment.

Exclusion Criteria

I have had a stem cell transplant from a donor.

I have had adoptive T cell therapy before.

I have received gene therapy before.

+4 more

Participant Groups

The study tests the effectiveness and safety of a drug called tisagenlecleucel in treating Follicular Lymphoma that's either stopped responding to standard treatments or has returned after treatment.

1Treatment groups

Experimental Treatment

Group I: CTL019Experimental Treatment1 Intervention

All patients who received tisagenlecleucel infusion.